 |
11 Diseases |  |
1 Trial |
|
1 Trial |  |
33 News |  |
- PF-04136309 / Pfizer
Determination of permissive and restraining cancer-associated fibroblast (DeCAF) subtypes (Section 36) - Mar 5, 2024 - Abstract #AACR2024AACR_7555;
P1
Analysis of a phase Ib trial FOLFIRINOX in combination with a CCR2 inhibitor (PF-04136309; NCT01413022) , we found that in patients with classical tumors, increasing permCAF probability was associated with response (r = -0.688, p<0.001)...DeCAF subtypes are associated with histological subtype in MESO (p = 0.021) and grade in KIRC (p = 0.056). Taken together, DeCAF subtypes explain the role of CAF subtypes in patients, provide a foundation for the translation of preclinical studies, and facilitate the design of future therapeutic approaches and clinical trials.
- | gemcitabine / Generic mfg.
Journal: Overcoming pancreatic cancer immune resistance by codelivery of CCR2 antagonist using a STING-activating gemcitabine-based nanocarrier. (Pubmed Central) - Jan 19, 2024
Our work has shed light to the multi-faceted role of STING activation and provided a novel immunotherapy regimen to maximize the benefit of STING activation for PDAC treatment. In addition, this work paved a new way for bioinformatics and computer modeling-guided rational design of nanomedicine.
- | PF-04136309 / Pfizer, Bindarit (AF 2838) / Angelini Group
Preclinical, Journal: Chemokine CCL2 promotes cardiac regeneration and repair in myocardial infarction mice via activation of the JNK/STAT3 axis. (Pubmed Central) - Dec 12, 2023
We demonstrated in NRVMs that the CCL2 stimulated cardiomyocyte proliferation through STAT3 signaling: treatment with rCCL2 (100?ng/mL) significantly increased the phosphorylation levels of STAT3, whereas a STAT3 phosphorylation inhibitor Stattic (30??M) suppressed rCCL2-induced cardiomyocyte proliferation. In conclusion, this study suggests that CCL2 promotes cardiac regeneration via activation of STAT3 signaling, underscoring its potential as a therapeutic agent for managing MI and associated heart failure.
- PF-04136309 / Pfizer
Bioinformatics and computer modeling-guided polymeric formulation for overcoming pancreatic cancer immune resistance (S103d (McCormick Place Convention Center)) - Aug 9, 2022 - Abstract #ACSFall2022ACS_Fall_5710;
Through the combination of computer modeling and experimental screening, we developed a dual delivery modality by incorporating a CCR2 (the receptor shared by both CCL2 and CCL7) antagonist PF-6309 (PF) into the polymeric carrier system...Our work has shed light to the multi-faceted role of STING activation and provided a novel immunotherapy regimen to maximize the benefit of STING activation for PDAC treatment. In addition, this work paved a new way for bioinformatics and computer modeling-guided rational design of nanomedicine.
- PF-04136309 / Pfizer, Turalio (pexidartinib) / Daiichi Sankyo
HYPERGLYCEMIA SENSITIZES PANCREATIC CANCER TO MACROPHAGE-SPECIFIC IMMUNOTHERAPIES: AN UPDATE (Bayview Ballroom) - May 10, 2022 - Abstract #APCM2022APCM_91;
Hyperglycemia appears to sensitize PC to an otherwise ineffective CSF1R inhibitor. We are currently testing the efficacy of D30 and pexidartinib in a model of hepatic metastases and studying effectiveness of D30 combined with PF-4136309, a CCR2 inhibitor.
- | PF-04136309 / Pfizer
Journal, Myeloid-derived suppressor cells: GOLM1 Drives Colorectal Cancer Metastasis by Regulating Myeloid-derived Suppressor Cells. (Pubmed Central) - Nov 5, 2021
PF-04136309, a small molecule and specific inhibitor of CCR2 can largely suppressed GOLM1-mediated CRC metastasis. These results suggest that GOLM1 can promote CRC metastasis and is a prognostic biomarker in human CRC.
- || zoledronic acid / Generic mfg.
Review, Journal: Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy. (Pubmed Central) - Sep 3, 2021
To date, TAM-targeted therapeutic strategies have mainly been divided into two kinds: inhibiting pro-tumor TAMs and activating anti-tumor TAMs. We reviewed the heterogeneous and plastic characteristics of macrophages in the TME and the feasible strategies to target TAMs in cancer immunotherapy and summarized the complementary effect of TAM-targeted therapy with traditional treatments or other immunotherapies.
- || PF-04136309 / Pfizer, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical, P1 data, Journal, Combination therapy: Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. (Pubmed Central) - Jun 2, 2021
P1b/2
Conclusions PF-04136309 in combination with nab-paclitaxel plus gemcitabine had a safety profile that raises concern for synergistic pulmonary toxicity and did not show an efficacy signal above nab-paclitaxel and gemcitabine. ClinicalTrials.gov identifier: NCT02732938.
- PF-04136309 / Pfizer
Trial termination, Combination therapy, Metastases: Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (clinicaltrials.gov) - Jan 9, 2018
P1b/2, N=21, Terminated, Sponsor: Pfizer
ClinicalTrials.gov identifier: NCT02732938. Completed --> Terminated; Pfizer made a business-related decision on 04May2017 to terminate study based on change in portfolio prioritization, and is not due to safety or efficacy.
- | PF-04136309 / Pfizer
Trial completion, Combination therapy, Metastases: Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (clinicaltrials.gov) - Nov 6, 2017
P1b/2, N=21, Completed, Sponsor: Pfizer
Completed --> Terminated; Pfizer made a business-related decision on 04May2017 to terminate study based on change in portfolio prioritization, and is not due to safety or efficacy. Active, not recruiting --> Completed
- | PF-04136309 / Pfizer
Enrollment change, Trial primary completion date, Combination therapy, Metastases: Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (clinicaltrials.gov) - Sep 8, 2017
P1b/2, N=21, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed N=112 --> 21 | Trial primary completion date: Dec 2017 --> Sep 2017
- | PF-04136309 / Pfizer
Journal: Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. (Pubmed Central) - Jun 15, 2017
P1
N=112 --> 21 | Trial primary completion date: Dec 2017 --> Sep 2017 CCR2-targeted therapy with PF-04136309 in combination with FOLFIRINOX is safe and tolerable.
- ||| PF-04136309 / Pfizer
Enrollment closed, Combination therapy, Metastases: Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (clinicaltrials.gov) - May 24, 2017
P1b/2, N=112, Active, not recruiting, Sponsor: Pfizer
CCR2-targeted therapy with PF-04136309 in combination with FOLFIRINOX is safe and tolerable. Recruiting --> Active, not recruiting
- || PF-04136309 / Pfizer
Trial primary completion date, Combination therapy, Metastases: Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (clinicaltrials.gov) - May 19, 2017
P1b/2, N=112, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2019 --> Dec 2017
- || PF-04136309 / Pfizer
Trial primary completion date, Combination therapy, Metastases: Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (clinicaltrials.gov) - Apr 25, 2017
P1b/2, N=112, Recruiting, Sponsor: Pfizer
Trial primary completion date: Jul 2019 --> Dec 2017 Trial primary completion date: Nov 2018 --> Jul 2019
- || PF-04136309 / Pfizer
Trial primary completion date, Combination therapy, Metastases: Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (clinicaltrials.gov) - Oct 21, 2016
P1b/2, N=112, Recruiting, Sponsor: Pfizer
Trial primary completion date: Nov 2018 --> Jul 2019 Trial primary completion date: Aug 2018 --> Nov 2018
- PF-04136309 / Pfizer
Trial completion, Metastases: FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Sep 19, 2016
P1, N=44, Completed, Sponsor: Washington University School of Medicine
Trial primary completion date: Aug 2018 --> Nov 2018 Active, not recruiting --> Completed
- | PF-04136309 / Pfizer
Phase classification, Combination therapy, Metastases: Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (clinicaltrials.gov) - Jun 22, 2016
P1b/2, N=112, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Phase classification: P1 --> P1b/2
- | PF-04136309 / Pfizer
Trial completion: Food Effect Study PF-04136309 (clinicaltrials.gov) - May 27, 2016
P1, N=18, Completed, Sponsor: Pfizer
Phase classification: P1 --> P1b/2 Recruiting --> Completed
- ||| PF-04136309 / Pfizer
Enrollment open, Combination therapy, Metastases: Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (clinicaltrials.gov) - May 9, 2016
P1, N=112, Recruiting, Sponsor: Pfizer
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| PF-04136309 / Pfizer
New P1 trial, Combination therapy, Metastases: Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (clinicaltrials.gov) - Apr 11, 2016
P1, N=112, Not yet recruiting, Sponsor: Pfizer
- PF-04136309 / Pfizer
Enrollment open: Food Effect Study PF-04136309 (clinicaltrials.gov) - Dec 11, 2015
P1, N=18, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | PF-04136309 / Pfizer
New P1 trial: Food Effect Study PF-04136309 (clinicaltrials.gov) - Nov 6, 2015
P1, N=18, Not yet recruiting, Sponsor: Pfizer
- PF-04136309 / Pfizer
Enrollment closed, Metastases: FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Mar 10, 2015
P1, N=44, Active, not recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- PF-04136309 / Pfizer
Trial primary completion date, Metastases: FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Feb 5, 2015
P1, N=44, Recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2015 --> Oct 2013
- PF-04136309 / Pfizer
Enrollment change, Metastases: FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jun 27, 2013
P1, N=44, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Feb 2015 --> Oct 2013 N=56 --> 44
- PF-04136309 / Pfizer
Enrollment open, Metastases: FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Mar 26, 2012
P1, N=44, Recruiting, Sponsor: Washington University School of Medicine
N=56 --> 44 Not yet recruiting --> Recruiting
- PF-04136309 / Pfizer
New P1 trial, Metastases: FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Aug 7, 2011
P1, N=44, Recruiting, Sponsor: Washington University School of Medicine